Clinical Summary: GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney Disease
Adults with bipolar disorder and chronic kidney disease face high renal risk, often while taking psychotropics with nephrotoxic potential such as lithium, yet the article notes that no FDA-approved intervention currently exists to slow CKD progression in individuals with BD. This study asks whether GLP-1 receptor agonists, increasingly used in medically complex patients, are associated with lower kidney replacement therapy risk in this high-risk psychiatric population.
Key Findings
- Compared with DPP-4 inhibitor users, GLP-1 RA use was associated with significantly lower observed risk of kidney replacement therapy (aHR 0.56, 95% CI 0.50–0.64; P<.001).
- In the secondary active-comparator analysis, GLP-1 RA use was also associated with lower observed risk of kidney replacement therapy versus RAAS inhibitors (aHR 0.66, 95% CI 0.55–0.78; P< .001).
- After propensity score matching (n=3,908 per group), 5-year event-free survival for kidney replacement therapy was 87.93% among GLP-1 RA users versus 84.63% among DPP-4 inhibitor users (absolute risk reduction 3.30%; χ21=15.40; P <.001).
- Against RAAS inhibitors, Kaplan–Meier analyses showed higher 5-year kidney replacement therapy-free survival with GLP-1 RAs (94.68% vs 89.77%; log-rank χ21=17.66; P <.001), with a 4.91 percentage point absolute reduction in KRT and number needed to treat, 21; P <.001.
- Health care utilization findings were less stable: the primary analysis favored GLP-1 RAs versus DPP-4 inhibitors (aHR 0.74, 95% CI 0.71–0.78; P <.001), but after matching there was no significant difference in 5-year event-free survival (58.06% vs 60.64%; χ21=0.018; P =.893).
In adults with bipolar disorder and chronic kidney disease, GLP-1 receptor agonist use was consistently associated with lower kidney replacement therapy risk across multiple analyses and comparators. The renal signal was stronger and more reproducible than the health care utilization signal, which did not hold in propensity-matched survival analyses.
Practice Implications
- For patients with bipolar disorder and CKD who are already candidates for GLP-1 receptor agonists, renal risk deserves a place in treatment discussions alongside metabolic indications, because the observed kidney replacement therapy association was consistent versus both DPP-4 inhibitors and RAAS inhibitors.
- Do not overinterpret reduced health care utilization as an established benefit: although the primary Cox model showed lower HCU risk (aHR 0.74, 95% CI 0.71–0.78; P <.001), propensity-matched Kaplan–Meier analyses were not significant versus DPP-4 inhibitors or RAAS inhibitors.
- Lithium-treated patients warrant particular multidisciplinary attention: the kidney replacement therapy association remained significant in the lithium subgroup (aHR 0.41, 95% CI 0.24–0.71; Q=.001), while the article notes known GLP-1 RA–associated lithium toxicity risks and the need for prospective safety monitoring.
- Use these data to prompt psychiatry-nephrology-endocrinology collaboration rather than to make stand-alone prescribing recommendations, because the study was retrospective and hypothesis-generating despite balanced propensity-matched analyses and null negative controls.
